Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 132

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 132
---
 to pursue patent protection in certain jurisdictions,
and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope. It
is also possible that we will fail to identify patentable aspects of our discovery and preclinical development output before it is too
late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution
of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and
applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.

The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much
litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States.
Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United
States and other jurisdictions are typically not published until 18 months after filing, or in limited cases not at all. Therefore, we
cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent
applications, or that we were the first to file for patent protection of such inventions. Also, an examination is often lengthy and can
involve numerous challenges to the claims sought. As a result, the issuance, scope, validity, enforceability and commercial value of our
patent rights are highly uncertain. Pending and future patent applications may not result in patents being issued which protect our technology
or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes
in either the patent laws or interpretation of the patent laws in the United States, the European Union, and other countries may diminish
the value of the underlying patents under our License Agreement or narrow the scope of our patent protection.

Any inability by us to adequately protect the underlying
intellectual property with respect to proprietary technology and products we plan to develop may have a material adverse effect on our
business, operating results, and financial position.

If we successfully identify new product candidates
and license those rights, we may fail to comply with our obligations under any potential license in which we may license intellectual
property and other rights from third parties or otherwise experience disruptions to our business relationships with our future licensors,
and we could lose those rights or other rights